An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma

Trial Profile

An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs TAK 580 (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 27 Mar 2018 Planned End Date changed from 1 Mar 2018 to 30 Sep 2018.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top